ABSTRACT
Background: Prone positioning (PP) is a well-known respiratory support approach. Limited data are available for the use of PP in nonintubated patients with COVID-19. Aim: This study aims to investigate the effect of PP on the clinical outcomes of patients with COVID-19 pneumonia. Methods: In this clinical trial, the participants in the PP group (n = 41) were asked to lie comfortably in a PP for 90 min. In the supine position (SP) group (n = 41), the participants were asked to lie comfortably in a SP for 90 min. Clinical data such as oxygen saturation, respiratory rate (RR), the severity of dyspnoea, mean arterial pressure (MAP), and pulse rate were assessed at 0 (immediately before), 30, 60, and 90 min after the start of the intervention, and 30 min after resuming the SP. The participants in the PP group were then asked to intermittently stay in a PP for a total of 8 h per 24 h of hospitalisation. The participants in the control group were asked to remain in their usual positions during the hospital stay. Finally, the length of hospital stay, intubation rate, and survival were assessed. Findings: PP was associated with significant improvement in oxygen saturation (P = 0.001), RR (P = 0.004), the severity of dyspnoea (P = 0.014), and MAP (P = 0.027). There was no significant difference between the two groups in terms of pulse rate (P = 0.890), hospital stay (P = 0.994), intubation rate (P = 0.324), and survival (P = 0.091). Discussion: Our results demonstrated that PP showed marked improvement in some short-term clinical outcomes in nonintubated patients with COVID-19. Conclusion: PP can be considered an inexpensive, accessible, and simple measure in awake nonintubated patients with COVID-19.
ABSTRACT
INTRODUCTION: Since the emergence of the novel coronavirus, herbal medicine has been considered a treatment for COVID-19 patients. This study was done to determine the efficacy of olive leaf extract on the outcomes of COVID-19 patients. MATERIALS AND METHODS: This randomized, triple-blinded clinical trial was conducted on hospitalized COVID-19 patients. Using block randomization, eligible patients were allocated to the following groups: intervention A received olive leaf extract (250 mg every 12 hours for five days), intervention B received olive leaf extract (500 mg every 12 hours for five days), and the control group received placebo (every 12 hours for five days). The outcomes (vital signs, laboratory tests, and length of hospitalization) were compared by group. RESULTS: Of the 150 patients randomized into groups, 141 completed the follow-up and were analyzed. On the fifth day of hospitalization, body temperature (MD=0.34, P<0.001), pulse rate (MD=5.42, P=0.016), respiratory rate (MD=1.66, P=0.001), ESR (MD=13.55, P<0.001), and CRP (MD=15.68, P<0.001) of intervention A were significantly lower than the control group, while oxygen saturation (MD= -1.81, P=0.001) of intervention A was significantly higher than the control group. Furthermore, body temperature (MD=0.30, P=0.001), pulse rate (MD=5.29, P=0.022), respiratory rate (MD=1.41, P=0.006), ESR (MD=14.79, P<0.001), and CRP (MD=16.28, P<0.001) of intervention B were significantly lower than the control group, while oxygen saturation (MD= -2.38, P<0.001) of intervention B was significantly higher than the control group. CONCLUSION: Olive leaf extract can improve the clinical status of the patients and decrease the length of hospitalization.